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Abstract
Objectives
This study aims to analyze the mortality and the length of ICU stay (LOS) of A. baumannii
VAP compared to respiratory colonization in patients with mechanical ventilation (MV).
Methods
A prospective cohort study was performed in an ICU of adult patients (February 2010–June
2011). One hundred patients on MV with A. baumannii in lower respiratory airways were
recruited, and classified as VAP or airways colonization according to CPIS criteria, with a
punctuation6. LOS, 30-days mortality, A. baumannii bacteremia, and clinical features
including antibiotic therapy were recorded. Multivariate analysis (linear and Cox regression)
and survival analysis (Kaplan-Meier curves) were performed.
Results
Fifty-seven VAP and 43 colonized A. baumannii patients were analyzed. Among the A. bau-
mannii strains, 99% were non-susceptible to carbapenems and the MIC90 of colistin was 0.12
mg/l. Therapy was appropriate in 94.6% of VAP patients, most of them with colistin 6 MIU/day,
although in 13 (23.6%) cases colistin was started 48 hours after the onset of VAP. Mortality was
similar in both groups (VAP 24.6% vs. colonized 27.9%, p = 0.7). Bacteremia and acute kidney
insufficiency were associated with decreased survival (p = 0.02 and p = 0.04, respectively) in
VAP patients. LOS was 21.5 (11.5–42.75) vs. 9 (6–22) days for VAP and colonized patients
(p = 0.004). VAP (p = 0.003) and age (p = 0.01) were independently related to a longer LOS.
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Conclusions
Multidrug-resistant A. baumannii VAP treated with colistin does not have a different mortality
compared to lower airways colonization, among patients on mechanical-ventilation, in a set-
ting of high susceptibility to colistin of A. baumannii.
Introduction
Acinetobacter baumannii is among the leading etiologies of hospital-acquired infections world-
wide, ventilator-associated pneumonia (VAP) being the most common among them [1].
Attributable mortality of A. baumannii infections can be heterogeneous, depending on under-
lying conditions and appropriateness of antibiotic therapy, but it may have been as high as
28.5–44.5% [2].The studies that have assessed the attributable mortality of A. baumannii VAP
usually included either patients with VAP caused by other pathogens or patients without any
pulmonary infection [2–3] in the control group. Since the risk factors for acquisition of A. bau-
mannii can be also associated to higher mortality (wide-spectrum antibiotic therapy, invasive
devices and procedures, clinical severity, duration of the ICU stay) [4–5], attributable mortality
of A. baumannii could be overestimated despite the efforts made to avoid confusing factors.
Thus, mechanically ventilated patients with lower airways colonization by A. baumannii may
be the most appropriate control group to weigh up the clinical impact of the A. baumannii
VAP, considering that around half of all the patients acquiring A. baumannii in the respiratory
tract develop VAP, while the others remain just colonized [6],and that risk factors for acquisi-
tion of A. baumannii are similar for both groups [5].
The spread of multidrug-resistant (MDR) strains, most of them resistant to carbapenems,
has greatly complicated the management of A. baumannii infections. Colistin, which conserves
activity against most clinical isolates of MDR A. baumannii, has emerged as its first-line ther-
apy. However, the traditional dosing regimen of colistin (6million of international units
[MIU] daily, tid) was considered insufficient to treat susceptible pathogens with a minimal
inhibitory concentration in the upper limit of susceptibility, according to the results of multi-
ple pharmacokinetics studies [7–8]. Consequently, higher dosages of colistin have been gener-
ally adopted, although a definitive consensus is lacking [9] and a loading dose is recommended
to achieve early effective concentrations in critically ill patients [10]. In our center, where a
predominance of carbapenem-resistant A. baumannii has been observed since 2008, the tradi-
tional dosages were used until 2011, when a new protocol was slowly adopted (loading dose of
4.5–6 MIU and 9 MIU daily, bid or tid).
The aims of this study were: i) To analyze the impact on mortality and ICU length of stay
(LOS) of A. baumannii VAP compared to lower airways colonization in mechanically venti-
lated patients; ii) To evaluate the efficacy of the different dosages of colistin in A. baumannii
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Setting and period
The study was conducted at the University Hospital Virgen del Rocı́o, a tertiary-care hospital
with 1,251 beds, including 62 adult ICU beds. The enrollment period was from February 2010
to June 2011.
Criteria of inclusion and exclusion
Adult patients (18 years) admitted to the ICU and requiring invasive mechanical ventilation
for more than 48 hours, and having at least one culture of trachea-bronchial aspirate (BAS)
with A. baumannii isolation. Patients with history of previous endotracheal intubation in the
preceding 365 days, tracheotomy or cystic fibrosis, were excluded.
Recruitment and follow up
Daily, two of the researchers identified the new candidates among ICU patients with MV.
After obtaining the informed consent, their baseline characteristics were collected in a stan-
dardized form and BAS cultures were performed every three days while intubated, up to 30
days. If A. baumannii was isolated, patients were definitively included in the study cohort and
followed until hospital discharge, death or 30 days, which ever occurred first. All clinical deci-
sions were made by the physicians in charge of the patients.
Variables
Patient demographics, primary diagnosis, in-hospital admission department, APACHE II [11]
and Charlson comorbidity Score [12] were recorded at the moment of inclusion. Antimicro-
bial therapy reception, and development of any cause of septic shock or acute kidney injury
(AKI) were recorded if they happened at any time during the follow-up, as well as ICU LOS
and mortality.
Patients were classified as A. baumannii VAP or lower airways colonization according to
the CPIS score, being classified as VAP those cases with a punctuation6 [13]. Septic shock
[14] and AKI [15] were defined according to standard criteria. Appropriate antimicrobial ther-
apy was considered when VAP patients received at least one drug active against the A. bau-
mannii isolates. Mortality was defined as death from any cause within 30 days after the first A.
baumannii isolation in colonized patients or after the onset of pneumonia in infected patients.
ICU stay was measured from the first isolation of A. baumannii.
Microbiological procedures
BAS were processed immediately for quantitative cultures. One hundred μL aliquots of serial
ten-fold dilutions were plated on Columbia sheep blood agar and incubated at 37˚C. Colony
forming units (CFUs) were counted after 24 h and expressed as log10 CFU/mL. Blood cultures
were processed in a BACTEC™ system. A. baumannii identification was performed by bio-
chemical tests in an automatized multi-test system (MicroScan Walkaway™), and by matrix-
assisted laser desorption ionization–time-of-flight (MALDI-TOF) analysis using a MALDI
biotyper (Bruker Daltonics). Among isolates from BAS, the first one from colonized patients
and the first at the diagnosis in patients with VAP were selected for antimicrobial susceptibility
testing. Minimum inhibitory concentrations for imipenem, sulbactam, ceftazidime, amikacin,
ciprofloxacin, tigecycline, colistin, and rifampin were performed by the broth microdilution
according to the CLSI criteria [16]. Isolates were defined as multi-drug resistant (MDR)
according to the standard criteria [17]. In those isolates resistant to imipenem, PCR amplifica-
tions were done to detect the presence of the oxacillinasesblaOXA51, blaOXA23, blaOXA24,
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blaOXA58, and the metallo-β-lactamases (MBL) IMP and VIM genes [18–19]. Expression of
blaOXA51 was assessed testing by PCR the presence of the sequence ISAba1 upstream and the
gene encoding blaOXA51 [20].
Sample size
For the sample size, assuming 49,25% mortality in patients with A. baumannii VAP (average
mortality of A. baumannii VAP in two studies performed in our centre [3,21]) and 20% in
respiratory colonization [6], and an infected and colonized ratio of 1:1, a minimum of 40
evaluable patients per group were required, with an alpha error of 5% and a power of 80%.
Statistical analysis
Discrete variables were expressed as counts (percentage) and continuous variables as the
median and interquartile range or mean and standard deviation, as appropriate. ICU stay anal-
ysis was made only on patients who survived until discharge from the ICU. Logarithmic trans-
formation was performed if length of stay variables did not show linear distribution.
Differences in categorical variables were calculated using a two-sided likelihood ratio chi-
square test or Fisher exact test, and the t-test or Mann-Whitney test was used for continuous
variables, when appropriate. Survival was analyzed by Kaplan-Meier curves. Back stepped Cox
regression was used to assess the factors independently associated to survival. Results are pre-
sented as the hazard ratio (HR) and 95% confidence interval (CI). Linear regression was used
for multivariate analysis in the case of ICU LOS, including the variables with a p<0.05 in the
bivariate analysis. Statistical significance was defined as p<0.05. The PASW 18.0 package was
used.
Results
During the study period, 285 eligible patients were identified in the ICU. A. baumannii was
isolated from respiratory samples in 100 of them: 57 were classified as VAP, with an average
CPIS score of 6.36±1.14, and 43 as lower airways colonization, respectively (Fig 1). The elapsed
time from intubation to the first isolate was 9 (5–14) days.
Colonized and VAP patients had similar demographic and clinical characteristics, as
detailed in Table 1. Fifty-three (92.9%) infected patients received appropriate therapy with
colistin and one (1.7%) with tigecycline; in 13 (23.6%) cases, colistin was started 48 hours after
the onset of VAP. Among patients who received colistin, loading dose was not used and all of
them received dosages of 2 MIU of sodium colistimethate thrice daily, titrated on renal func-
tion when appropriate.
There were no differences in the mortality of patients with A. baumannii VAP regarding to
those with airways colonization (Table 1), and so did their survival rate according to the
Kaplan-Meier analysis (p = 0.3) (Fig 2A). Patients with bacteremic VAP had a trend to higher
mortality than VAP patients without bacteremia (42.9% vs. 20.9%, p = 0.1); and the survival
Kaplan-Meier analysis showed lower survival in bacteremic patients (p = 0.02) (Fig 2B). In the
multivariate survival analysis, colistin was associated to a better survival in patients with VAP,
while bacteremia and AKI were related to poor prognosis (Table 2).
Median ICU LOS was 17 days (8–33) for the whole sample, and 9 (6–22) vs. 21.5 (11.5–
42.75) days for colonized and VAP patients, respectively (p = 0.004). Development of A. bau-
mannii VAP (p = 0.003) and elder age (p = 0.013) were independently associated to a longer
ICU stay (Table 3).
Antimicrobial susceptibility is detailed in Table 4. Just one isolate was susceptible to imipe-
nem. The MIC90 of colistin was 0.12mg/L. Ninety (90%) isolates were MDR.blaOXA51, which
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is constitutive in A. baumannii, was present in all the isolates, but just 9 of them presented the
upstream sequence ISAba-1. blaOXA58 was present in 81 isolates and blaOXA40 in 18 isolates,
with an imipenem MIC50 of 16 and 64 mg/L, respectively (p<0.001); none of them were MBL
producers. There were no differences in antimicrobial susceptibility/resistance between iso-
lates from colonized and VAP patients.
Discussion
In this prospective cohort, A. baumannii VAP did not produce an excess of mortality with
respect to the lower airways colonization by the same pathogen in critically ill patients on MV.
Nonetheless, VAP patients had a longer ICU stay, which points out the morbidity that it causes
among patients on mechanical ventilation. Colistin at traditional low doses was used in almost
all the patients with VAP; the high susceptibility to this drug among the A. baumannii isolates
Fig 1. Flow chart on the enrollment of patients in the study and final classification as ventilator-associated pneumonia (VAP) or
colonization in those with isolation of Acinetobacter baumannii in trachea-bronchial aspirate (BAS).
doi:10.1371/journal.pone.0168468.g001
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(MIC90 = 0.12 mg/L) could explain the lack of differences in mortality. Inside the group of
patients with VAP, bacteremia had a poorer survival rate (p = 0.02). Given that the impact on
Table 1. Distribution of baseline and clinical features among patients with A. baumannii lower airways colonization and those with A. baumannii
VAP.
Colonization VAP p
(n = 43) (n = 57)
Age 66 (43–70) 51 (43.5–69.5) 0.186
med (IQR)
Female sex 17 (39.5) 22 (38.6) 0.920
n (%)
Charlson score 1 (0–2) 0 (0–2) 0.529
med (IQR)
Chronic heart failure 7 (16.3) 6 (10.5) 0.397
n (%)
COPD 5 (11.6) 6 (10.5) 0.862
n (%)
DM 9 (20.9) 11 (19.3) 0.840
n (%)
AIDS 0 1 (1.8) 0.383
n (%)
Chronic liver disease 1 (2.3) 2 (3.5) 0.215
n (%)
Medical patient 24 (52.2) 22 (38.6) 0.084
n (%)
Surgical patient 8 (18.6) 17 (29.8) 0.200
n (%)
Trauma patient 11 (25.6) 18 (31.6) 0.510
n (%)
APACHE II 17 (12–21.25) 17 (13–20) 0.947
med (IQR)
Previous antibiotic therapy 40 (93) 53 (92.9%) 0.994
n (%)
Carbapenems 13 (30.2) 33 (57.9) 0.006
n (%)
Piperacillin-tazobactan 10 (23.2) 25 (43.8) 0.032
n (%)
Quinolones 14 (32.6) 14 (24.6) 0.378
n (%)
Vancomycin 6 (13.9) 22 (38.6) 0.007
n (%)
Acute kidney injury 13 (30.2) 27 (47.4) 0.085
n (%)
Septic shock 17 (39.5) 30 (52.6) 0.194
n (%)
Surgery 19 (44.2) 38 (66.7) 0.025
n (%)
Mortality 12 (27.9) 14 (24.6) 0.700
n (%)
doi:10.1371/journal.pone.0168468.t001
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Fig 2. a) Survival Kaplan-Meyer analysis between Acinetobacter baumannii colonized and ventilator-associated pneumonia (VAP)
patients (Blue: Colonized patients; Green: VAP patients); b) Survival Kaplan-Meyer analysis among patients with Acinetobacter baumannii
ventilator-associated pneumonia, with or without bacteremia. (Blue: non-bacteremic VAP patients; Green: bacteremic VAP patients).
doi:10.1371/journal.pone.0168468.g002
Table 2. Bivariate and multivariate survival analysis for mortality in patients with A. baumannii ventilator-associated pneumonia.
Variable Dead Survivors Bivariate Multivariate
(n = 14) (n = 43) HR (95%CI) p HR (95%CI) p
Female sex 7 (50) 15 (34.9) 1.22 (0.42–3.48) 0.710
n (%)
Age 58 (43.25–76.75) 49 (43–65) 1.01 (0.97–1.04) 0.580
med (IQR)
Charlson Score 2 (0.75–2.25) 0 (0–1) 1.27 (0.95–1.7) 0.107
med (IQR)
APACHE II 19.5 (17.75–20.25) 15.5 (12.25–19.5) 1.01 (0.95–1.08) 0.632
med (IQR)
Medical patient 8 (57.1) 14 (32.6) 2.27 (0.79–6.57) 0.129
n (%)
Surgical patient 5 (35.7) 12 (27.9) 1.38 (0.46–4.13) 0.563
n (%)
Trauma patient 1 (7.1) 17 (39.5) 0.15 (0.02–1.12) 0.064
n (%)
Septic shock 11 (78.6) 19 (44.2) 2.26 (0.63–8.13) 0.212
n (%)
Acute kidney injury 11 (78.6) 16 (37.2) 3.5 (0.97–12.54) 0.055 3.88 (1.06–14.21) 0.04
n (%)
Colistin 13 (92.9) 40 (93.0) 0.03 (0.002–0.47) 0.013 0.02 (0.001–0.72) 0.033
n (%)
Bacteremia 6 (42.9) 9 (20.9) 4.49 (1.52–13.3) 0.007 4.67 (1.53–14.25) 0.02
n (%)
doi:10.1371/journal.pone.0168468.t002
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mortality of VAP is related to its severity [21], the presence of concomitant A. baumannii bac-
teremia, whose crude mortality in the setting of pneumonia is high [22], can be understood as
a key event that warns on severity and invasiveness of the VAP. A previous surgical procedure
was more frequent in VAP than in colonized patients, but this feature was not associated to
mortality in the whole sample (data not shown).
The crude mortality described for any-cause VAP is usually higher, ranging between 34.5%
and 84% [3,23–25]. In this context, A. baumannii VAP has been associated to higher mortality
and longer LOS in ICU than VAP caused by other pathogens [21, 26–28]. For instance, in a
cohort of 163 patients with VAP, A. baumannii was identified as an independent risk factor
for fatal outcome (OR 3.3, CI 1.12–9.7), reaching a crude mortality of 61% [26]. Carbapenem-
resistance in A. baumannii has been associated to increased VAP mortality. A matched case-
control study comparing 60 patients with A. baumannii VAP and 60 controls (patients with
VAP caused by other microorganisms and patients without VAP), did not report differences
in mortality for the whole sample [3]. Nevertheless, the sub-analysis of the patients with VAP
by imipenem-resistant A. baumannii showed differences in mortality between cases and their
Table 3. Factors associated to the length of intensive care unit-stay (bivariate and multivariate analysis) in the whole cohort (n = 100).
Variable Bivariate analysis Multivariate analysis
p OR (95%CI) p OR (95%CI)
VAP * 0.007 1.81 (1.18–2.79) 0.004 1.88 (1.23–2.88)
Age 0.041 1.01 (1.00–1.03) 0.010 1.01 (1.00–1.03)
Female sex 0.097 1.45 (0.93–2.26) - -
Charlson Score 0.257 1.45 (0.90–1.44) - -
APACHE II 0.03 1.04 (1.00–1.07) 0.47 1.01 (0.98–1.05)
Septic shock 0.011 1.80 (1.15–2.81) 0.204 1.35 (0.85–2.15)
Acute kidney injury 0.015 1.84 (1.13–3.01) 0.107 1.5 (0.91–2.47)
Bacteremia 0.98 0.99 (0.50–1.97) - -
* VAP: ventilator-associated pneumonia
doi:10.1371/journal.pone.0168468.t003
Table 4. Antimicrobial susceptibility and mechanism of resistance to carbapenems in the isolates of A. baumannii.
Antimicrobial agent MIC range MIC50 MIC90 % susceptible isolates
Imipenem 0.25–256 16 128 1
Meropenem 0.38->8 >8 >8 1
Amikacin 0.25–64 8 32 78
Ceftazidime 16–256 64 128 0
Ciprofloxacin 0.5 32 128 0
Colistin 0.06–0.12 0.06 0.12 100
Rifampicin 1–128 32 128 15
Sulbactam 2–32 4 16 62
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matched controls (44% vs. 24%). In the present study, despite having found almost a 100% of
carbapenem-resistance, mortality was quite lower than that previously described for A. bau-
mannii VAP.
This discrepancy in the mortality could be explained by an unequal distribution in the
appropriateness of antibiotic therapy among different studies. A meta-analysis on 24,186
patients from 44 observational studies [28] found that VAP was associated with higher mortal-
ity (OR 1.96, 95%CI 1.26–3.04) than their comparative groups; notwithstanding, this associa-
tion was not found in VAP patients with appropriate initial treatment. The higher mortality of
VAP caused by more resistant strains is probably related to the less likelihood of receiving
appropriate therapy [21]. Therefore, despite the high level of resistance of the isolates included
in this study, the rate of VAP patients receiving appropriate treatment (95%) has probably
contributed to a lower mortality.
It is noteworthy that the antibiotic used for most patients in the present study was colistin,
which was selected as an independent predictor of better survival. Until it became almost the
only alternative, colistin was considered a last option for the treatment of A. baumannii infec-
tions due to concerns about its efficacy and safety. In a systematic review including all the stud-
ies assessing the efficacy of colistin compared to other antibiotics, the global analysis favored
the comparators [29]. However, several pharmacokinetics studies have prompted that this lack
of efficacy would be related to an insufficient antibiotic exposure, and higher doses have been
proposed to obtain an optimal drug concentration at the infection site [7–8]. Dose-fraction-
ation studies of colistin against A. baumannii in mouse infection models have revealed that
AUC/MIC correlates with bacterial killing in vivo [30], even though its optimal value has not
been well defined yet. In an A. baumannii murine pneumonia model, an AUC0-24/MIC of
158.8 was associated to a 3.78-log bacterial kill target in lungs and a reduction of 40% in mor-
tality [31]. Karnik et al. [32] performed a PK study in patients with VAP caused by multidrug-
resistant bacteria treated with 2 MU every 8 hours of colistin, the same kind of patients and
colistin dosage as used in the present study, achieving an AUC0-24 of colistin of 47.1 mg
.h/l.
Taking into account the colistin MIC90 of 0.12 mg/L for the A. baumannii strains causing VAP
in the present study, we would have achieved an average AUC0-24/MIC of 392.5 from the first
colistin dose. Therefore, the low MIC90 of the included strains may explain the high effective-
ness of the colistin therapy in this cohort of patients.
There is little further information on the association between MIC of colistin and effective-
ness, because most clinical studies do not provide the MIC of colistin against the included
strains. Markou et al. [33], in an observational study of 10 patients with A. baumannii infec-
tions, found that the MIC90 of colistin was higher among patients without clinical response to
this drug (1 vs. 0.5 mg/L); however, the small sample size and the likely confounding factors
preclude from assuming the impact of the MIC on the outcome. Recently, Kim et al. [34]
reported a similar efficacy of tigecycline and colistin in a cohort of 70 patients with A. bauman-
nii VAP. In this study, low tigecycline MIC was suggested as the reason for the good successful
rate and survival among patients treated with tigecycline; however, unfortunately, the informa-
tion regarding the precise colistin and tigecycline MIC was not reported.
In recent years, all efforts for the optimization of the treatment with colistin have been
aimed at enhancing its pharmacokinetics, targeting to obtain higher levels, although safety can
be of concern [35–36]. Focusing on strategies addressed to pharmacodynamics parameters
related to the colistin MIC90 against the A. baumannii strains in each hospital might help to
avoid over-dosage in some patients at risk of toxicity. With this strategy, the main concern
would be if low dosages might select more easily resistant strains. However, this drawback
seems to be ruled out by recent in vitro models, in which the emergence of resistant strains was
paradoxically increased with higher colistin concentrations [37–38].
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Our study has several limitations. First of all, the sample size was calculated a priori and the
observed mortality of VAP patients was lower than expected. This made our sample size sub-
optimal for detection of differences in mortality. Second, the method chosen for enrolling
patients, periodic quantitative BAS cultures, has probably prompted the early initiation of
appropriate antimicrobial therapy and influenced VAP outcome. Third, there is not a gold
standard to classify patients as suffering from VAP and the use of CPIS score and other crite-
ria, beyond the clinical ones, is a matter of debate; in fact, in the recent IDSA/ATS Guidelines
for the Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia
[39] the authors do not recommend any criteria, among those reviewed, to support or exclude
the HAP/VAP, because of low sensitivity and specificity. However, to avoid the selection bias
of the research it is necessary to use specific criteria, in spite of the problems with the sensitiv-
ity/specificity; in this context, we decided to use the CPIS score, because it includes the clinical
criteria (fever, purulent sputum, new infiltrates in the X-ray, respiratory insufficiency, and leu-
kocytosis), with different punctuation to compose the reached score value. Fourth, the possi-
bility of ventilator-associated trachea-bronchitis or airways infection produced by other
microorganisms, or the occurrence of different events including other infections after the
recovery or during the ICU stay that may have influenced individual outcomes, as is common
in critically ill patients, were not considered.
In summary, the present study shows that MDRA. baumannii VAP treated with colistin
does not have different mortality compared to lower airways colonization among patients on
mechanical-ventilation. The high susceptibility to colistin among the isolated strains probably
determined this similar outcome. In our opinion, this fact deserves special attention in rela-
tionship to the strategy in reaching the most appropriate treatment. Finally, bacteremic VAP
showed a decreased survival in comparison to non-bacteremic VAP.
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